We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunohistochemical Stain Facilitates cHL Diagnosis

By LabMedica International staff writers
Posted on 11 Mar 2019
Remarkable efforts are underway to exploit classic Hodgkin lymphoma's (cHL) complex interplay of molecular alterations, loss of B-cell programming, and dependency of tumor microenvironment.

Tumor necrosis factor receptor superfamily member 9 or CD137 has been shown to induce proliferation and enhance the survival and function of T cells, natural killer cells, and dendritic cells. More...
Conceptually, agonistic anti-CD137 is categorized as a co-stimulatory immunotherapy with the potential to manipulate the tumor microenvironment and accentuate antitumor response.

Pathologists at the Naval Medical Center Portsmouth (Portsmouth, VA, USA) and The University of New Mexico School of Medicine (Albuquerque, NM, USA) constructed tissue microarrays from formalin-fixed, paraffin-embedded tissue including 42 cases of cHL, 33 cases of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL), 16 cases of anaplastic large cell lymphoma, and seven cases of T-cell/histiocyte–rich large B-cell lymphoma. They validated anti-CD137 monoclonal BBK-2 clone, using protease retrieval and a dilution of 1:100.Tissue microarrays were then stained with CD137 as well as CD15, CD20, and CD30 and reviewed by two pathologists.

The scientists assigned positive staining if 20% or more of the malignant cells were positive regardless of strength of staining. Of the cHL cases, 76% were positive for CD137, 85% were positive for CD15, 100% were positive for CD30, and 13% were positive for CD20. Interestingly, CD137 was positive in all cHL cases where CD15 was negative. Conversely, CD15 was positive in 88% of cHL cases that were negative for CD137. Furthermore, CD137 was positive in 6% of NLPHL cases, 38% of anaplastic large cell lymphoma cases, and in none of the T-cell/histiocyte–rich large B-cell lymphoma cases.

The authors concluded that, although CD137 is not specific for cHL, it has utility in the immunohistochemistry (IHC) evaluation for cHL, in particular when the morphologic distinction with NLPHL is challenging. Additionally, it is easy to interpret, with minimal nonspecific background staining. Lastly, CD137 expression has been identified in several solid and hematopoietic neoplasms, and determination of this expression via IHC may prove to be a valuable biomarker of response to CD137 immunotherapy. The study was published in the March 2019 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Naval Medical Center Portsmouth
University of New Mexico School of Medicine


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.